FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA advisory panel recommended on Friday that compounding pharmacies be allowed to manufacture epitalon (7-4, for insomnia) and semax (8-5, for migraines and other neurological conditions), but voted 6-7 against emideltide for opioid withdrawal, chronic insomnia, and narcolepsy.
- Thursday's earlier votes added four other peptides to the 503A bulk drug substances list: BPC-157 (8-6, ulcerative colitis), KPV and TB-500 (for wound healing), and MOTS-c (7-5, for obesity and osteoporosis), bringing the two-day total to seven peptides advanced.
- FDA staff recommended against adding all seven peptides, citing a lack of clinical evidence on safety and efficacy; Mary Thanh Hai, director of the Office of New Drugs, noted that once a substance is on the 503A list, the FDA has no authority to require compounders to submit safety or efficacy data.
- Panelists voting yes largely had ties to the peptide industry and were appointed by HHS, while dissenters were mostly physicians from academic institutions and patient representatives — a split the article frames as a clash between the MAHA movement and mainstream science.
- Robert F. Kennedy Jr.'s push to broaden access to these unapproved peptides, popular via social media influencers, moves one step closer; the FDA is not bound by the panel's advice, and acting FDA commissioner Kyle Diamantas or Kennedy himself could overrule career staff before a proposed rule is published.
- Emideltide dissenter David Pope, chief pharmacy officer at XiFin Pharmacy Solution, broke from his previous majority votes to oppose the drug, citing "potentially dangerous downstream consequences" — while semax supporters noted it is already approved in Russia for clinical use.
Why it matters: The panel's votes test the limits of FDA approval norms: seven peptides with insufficient clinical evidence could soon be compounded legally, and FDA staff explicitly warned they lack authority to demand post-listing safety data — meaning once added, these compounds enter the market with no federal efficacy gatekeeping, a direct fulfillment of RFK Jr.'s MAHA agenda over the objections of career scientists.
